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Abstract: Bevacizumab in combination with interferon alfa is now approved for treatment-
naïve advanced renal cell carcinoma (RCC) in both the US and Europe. Its objective response 
rates of 30% and progression-free survival rates of 9–10 months are   comparable to the other 
approved first-line multityrosine kinase inhibitors, sunitinib and pazopanib. Its advantages 
include a different toxicity profile and assurance of   administration compliance given its intra-
venous formulation. Enthusiasm for its use is blunted by the increased costs, the potential 
infusion-related reactions, the associated interferon-related toxicities, and the inconvenience 
of its nonoral formulation. Further study is warranted to assess its efficacy both as a single 
agent and in combination with the targeted agents and other immunotherapies. With mul-
tiple agents now available for the treatment of advanced RCC, identification of patient and 
tumor-specific biomarkers to inform our choice of first-line therapy and the proper sequence 
of subsequent therapies is imperative.
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Introduction
Historically heralded as a disease resistant to most standard chemotherapies,1 
the treatment arsenal for advanced renal cell carcinoma (RCC) now boasts a 
relative plethora of active regimens. The discovery of etiological mutations and 
aberrations in the von Hippel–Lindau (VHL) gene in the majority of clear-cell 
RCCs is responsible for a marked shift from toxic   immunotherapy-focused 
treatments that were limited to selected patients to the more broadly applicable 
“targeted agents.” The growing understanding of the biologic changes respon-
sible for clear-cell RCC and the potential role of upregulated hypoxia-inducible 
genes led to investigation of agents that target the vascular endothelial growth 
factor (VEGF) pathway. The efficacy and utility of these agents would quickly 
be established, and in less than 6 years, the limited treatment armamentarium 
of 2 main immunotherapeutics in 2004 has blossomed into 6 US Food and Drug 
Administration (FDA)-approved drugs that directly or indirectly regulate VEGF 
and other growth factor pathways, with many more under investigation. This 
review will highlight one of these agents, bevacizumab, a monoclonal antibody 
to the VEGF-A ligand, and will detail the   biology behind the rational use, phar-
macology, efficacy, safety, tolerability, and role of bevacizumab in the current 
treatment of advanced RCC.OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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Biologic rationale for bevacizumab’s 
efficacy in RCC
VHL disease is an autosomal dominant disorder   characterized 
by a germline mutation in the VHL gene. It results in a 
syndrome characterized by benign and malignant tumors 
of the central nervous system and viscera. Approximately 
25%–60% of patients will develop RCC or cysts   generally 
by the time they are 40 years of age (median age 39 years, 
range 16–67 years).2 RCC is a common cause of death in this 
disorder. In contrast, somatic mutations and   aberrations in the 
VHL gene such as through loss of   heterozygosity and gene 
inactivation through methylation are the likely driving force 
behind the majority of sporadic clear-cell RCCs.3–7 Located 
on chromosome 3 (3p25-26), VHL is tumor suppressor gene 
that regulates hypoxia-inducible factors (HIF).8,9 In situations 
of normoxia, the VHL protein complexes with HIF1-α and 
HIF2-α, which acts as a signal for proteosome degrada-
tion. This signaling is disrupted in situations of hypoxia or 
aberrant VHL protein such that HIF is not degraded. Con-
stitutively activated HIF results in enhanced glucose uptake 
and increased expression of new blood vessels (angiogen-
esis), growth factors, and mitogens promoting tumor cell 
growth.9 Among those factors upregulated by HIF are the 
proangiogenesis genes, VEGF and platelet-derived growth 
factor (PDGF). VEGF stimulates endothelial cell growth and 
angiogenic processes integral to tumor growth.10,11 Inhibition 
of this upregulation has provided the biologic rationale for 
the anti-VEGF agents whether directed toward the ligand 
with antibodies such as bevacizumab or at the receptor level 
with the tyrosine kinase inhibitors (TKI), such as sunitinib 
or pazopanib.
Clinical development of 
bevacizumab and pharmacology
In 1997, Napoleon Ferrara’s group reported on their humaniza-
tion of the murine anti-VEGF monoclonal antibody A.4.6.1 
using site-directed mutagenesis of a human   framework.12 The 
humanized antibody achieved 90% inhibition of bovine capillary 
endothelial cell proliferation and 90%–95% tumor reduction in 
rhabdomyosarcoma and breast carcinoma cell line tumors in 
nude mice. This recombinant, humanized, monoclonal antibody 
(rhuMAb) to VEGF-A would later be known as bevacizumab or 
more commonly to the public as its proprietary name, Avastin®. 
Bevacizumab binds directly to all VEGF-A isoforms which 
suppresses activation of its receptors 1 (Flt-1) and 2 (KDR) 
on the surface of endothelial cells.13 This neutralization of the 
ligand–receptor interaction results in inhibition of endothelial 
cell proliferation and new blood vessel formation.
Initial pharmacokinetic studies of 491 patients, who 
received bevacizumab 1–20 mg/kg every 1–3 weeks, revealed 
a half-life of approximately 20 days with a time to steady 
state of 100 days.13 Higher bevacizumab clearance   correlated 
with male gender, higher body weight, and increased tumor 
burden. Doses as low as 0.3 mg/kg of bevacizumab are able 
to neutralize all detectable VEGF.14
Efficacy
An initial phase 1 study of single agent bevacizumab in 
25 patients with metastatic treatment refractory solid tumors 
suggested its potential efficacy in RCC.14 The drug was well 
tolerated at doses of 0.1–10 mg/kg given every 28 days. 
Although there were no partial responses (PR) or complete 
responses, 14 patients experienced clinical benefit in the form 
of minimal responses (2 patients) and disease stabilization (12 
patients). Interestingly, 1 of the 2 minimal responders and 5 of 
the 12 patients with stable disease had RCC. No patient devel-
oped antibodies to rhuMAb VEGF. This signal of efficacy and 
tolerability in RCC patients led to a randomized, 3-arm, single-
center phase 2 trial of bevacizumab in cytokine-refractory 
patients.15,16 In this trial, the efficacy and safety of low-dose and 
high-dose bevacizumab (3 mg/kg and 10 mg/kg administered 
every 2 weeks) was compared with a placebo control in 116 
patients. The majority (93%) of the patients had received prior 
interleukin-2 (IL-2). The trial was stopped early after an interim 
analysis showed that the 10 mg/kg dosage improved time to 
disease progression compared with the control (4.8 months 
vs 2.5 months, respectively; P , 0.001). The lower dosage 
did not achieve objective response rate (ORR) or significant 
improvement in time to progression (TTP) over placebo; 
median TTP was 3 months. The high-dose bevacizumab arm 
was well   tolerated with 10% of patients achieving a PR and 
59% (23/39)   experiencing disease stabilization for an overall 
disease control rate of nearly 70%.
Seeking to resist the “eventual tumor escape” observed in 
their bevacizumab monotherapy study, Yang and   colleagues16 
sought to enhance the antiangiogenic effects by combining 
low-dose bevacizumab with thalidomide. Known for its 
antiemetic and teratogenic properties, the biologic modi-
fier thalidomide is also thought to be antiangiogenic both 
directly by inhibiting basic fibroblast growth factor and 
VEGF and indirectly by blocking tumor necrosis factor α, 
a cytokine known to be secreted by RCC.17–19 Thalidomide 
had shown some efficacy in phase 2 trials in RCC with PR 
rates upwards of 20% (range 0%–17%) and 3–6 months of 
disease   stabilization rates of 8%–64% in 4 small, phase 2 
studies.20–23 Also of note was that this phase 2 combination trial OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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  represented the crossover arm of the placebo patients (n = 22) 
in their original 3-arm trial. These crossover patients were 
randomized either to bevacizumab alone (n = 10) or a com-
bination of low-dose bevacizumab and thalidomide (n = 12). 
Thalidomide 200 mg orally daily was titrated to a maximum 
of 800 mg daily. Bevacizumab was given as a loading dose of 
4.5 mg/kg intravenously (IV) followed by treatment doses of 
3 mg/kg every 2 weeks. No ORRs were seen in either group. 
Median TTP did not differ between the 2 groups (2.4 months 
vs 3.0 months in the combination arm) or when compared 
with the 37 patients who had been randomized to the low-dose 
bevacizumab arm in the first stage of the trial.
Further attempting to improve on the efficacy of 
bevacizumab, Hainsworth and colleagues24 investigated 
combined VEGF and epidermal growth factor receptor 
(EGFR)   blockade by adding the EGFR-TKI, erlotinib, to 
bevacizumab. Their rationale included prior evidence that 
transforming growth factor α, a known ligand for EGFR, is 
commonly elevated in RCC and cell line models demonstrat-
ing a correlation between EGFR inhibition and suppression 
of VEGF expression.25,26 In their single-arm, phase 2 trial, all 
patients were nephrectomized, and 68% were treatment-naïve. 
Median progression-free survival (PFS) was 11 months, and 
60% remained alive at 18 months. The ORR was 25% with 
an additional 61% experiencing stable disease at 8 weeks. 
Bukowski et al27 expounded on this work in a multicenter, 
placebo-controlled, randomized, phase 2 study that compared 
bevacizumab plus placebo to bevacizumab plus erlotinib in 
150 treatment-naïve metastatic RCC patients. No significant 
difference in RR (13.7% vs 14%, respectively) or PFS (8.5 
months vs 9.9 months, P = 0.58) was observed. An indirect 
comparison of the median PFS of 8.5 months in the mono-
therapy group compared favorably with historical data of 
patients receiving cytokines in this setting, that of 3.1 months 
for IL-2 and 4.7 months for interferon α (IFN).28,29
Seeking  to  eliminate  multiple  different  tumor 
  angiogenic mechanisms and to take advantage of the 
known   immunotherapy-sensitive nature of RCC, beva-
cizumab in combination with IFN has been evaluated 
and studies in combination with IL-2 are ongoing. Two 
large randomized controlled trials, CALGB 90206 and 
the global AVOREN trials, have investigated the efficacy 
of combination IFN and bevacizumab in the first-line 
treatment of advanced RCC30–33 (Table 1). In both trials, 
10 mg/kg of bevacizumab was administered IV every 2 
weeks with IFN (9 million units subcutaneously 3 times per 
week). The primary end point of both trials was initially 
overall survival (OS).
Between 2003 and 2005, 732 patients were enrolled in 
the CALGB trial.32,34 The majority were male (69%) with an 
Eastern Cooperative Oncology Group performance status 
of 0 (62%),   nephrectomized (85%), and were of intermedi-
ate risk by Motzer criteria (64%). Of the entire cohort, 350 
patients received IFN monotherapy and 366 patients received 
combination therapy. Median follow up was 46.2 months. The 
primary end point of OS did not significantly differ between 
the 2 groups: 18.3 months for bevacizumab plus IFN and 
17.4 months for IFN monotherapy (unstratified log-rank, 
P = 0.097). After adjusting for the stratification factors of 
nephrectomy status and number of adverse prognostic risk 
factors, the hazard ratio (HR) was 0.86 (P = 0.069). Neither 
nephrectomy status, Motzer risk score, presence of liver 
metastasis, age, nor gender impacted survival. Although no 
crossover to the bevacizumab arm was allowed during the 
trial, 62% of monotherapy patients and 54% of combina-
tion therapy patients received subsequent VEGF inhibitors. 
  However, the   addition of bevacizumab to IFN elicited a sig-
nificant 3 month benefit in PFS: 8.5 months compared with 
5.2 months in the   monotherapy arm (P , 0.0001). The ORR 
was significantly improved with bevacizumab: 25.5% vs 
13.1% (P , 0.0001). Median duration of response was 
11.9 months with the   combination. Limitations to this study 
included the lack of a placebo   control and an independent 
review of imaging.
Table 1 Comparison between the 2 bevacizumab randomized 
controlled phase 3 trials in advanced RCC
CALGB AVOREN
Sample size 732 649
Median age, y 61 61
Male patients,% 73% 68%
Performance status ($80% 
by KPS or $1 by eCOG)
98% 94%
Prior nephrectomy 85% 100%
MSKCC risk
Good 26% 27%
intermediate 64% 56%
Poor 10% 9%
Unknown 0% 9%
Placebo-controlled No Yes
Maximum weeks of iFN-α 
allowed by trial
None 52 
Assessment of efficacy investigator-assessed independent
Overall survival 18.3 vs 17.4 
(stratified, 
P = 0.097)
23.3 vs 21.3 
(stratified, 
P = 0.1291)
Progression-free survival, mo 8.5 vs 5.2 10.2 vs 5.4
Response rate 25.5% vs 13.1% 31% vs 13%
Abbreviations: RCC, renal cell carcinoma; MSKCC, Memorial Sloan-Kettering 
Cancer Center; iFN, interferon.OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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In terms of tolerability, more patients in the combination 
arm required dose reductions of IFN: 47% vs 64%, most 
commonly due to fatigue. The combination arm had more 
treatment delays (31.6% vs 61.7%) and grade $3 toxicity 
(80% vs 63%, P , 0.001), but notably, duration of   treatment 
was on average 4 months longer. The increased grade $3 
toxicities were significant for hypertension, anorexia, fatigue, 
and proteinuria. The majority of the patients (56%) in both 
arms discontinued for disease progression, and the groups 
were fairly equal in terms of discontinuing treatment due 
to toxicity: 24% in the combination arm and 21% in the 
monotherapy arm.
During a similar time period, a global placebo-controlled 
trial, known as AVOREN, investigated the combination of 
bevacizumab and IFN.30,31 The trial was initially designed 
with a primary end point of OS, but it was later changed to 
PFS because of concerns over potential confounders including 
the emergence of preliminary results of the CALGB trial and 
new second-line therapies that would become   available while 
the trial was in progress. This   amendment was permitted by 
both the European and US regulatory   agencies and allowed a 
preplanned final analysis of PFS data to be performed before 
the original primary end point OS data would be mature.
In 2004 and 2005, 649 of 821 screened patients were 
randomized either to bevacizumab and IFN or to placebo 
plus IFN. Unlike the CALGB trial where IFN was given 
until disease progression or intolerability, IFN was given 
for a maximum of 52 weeks. Bevacizumab/placebo was 
administered until progression or intolerable toxicity. The 
majority of patients were male with a $90% Karnofsky 
performance status (70%) and intermediate risk (56%). 
In contrast to the CALGB study, patients were required to 
have had nephrectomy and to have predominantly (.50%) 
clear-cell histology.
Independently assessed median PFS was significantly 
improved in the bevacizumab arm at 10.2 months   compared 
with 5.4 months in the control group (HR = 0.63; 95% 
  confidence interval [CI], 0.52–0.75, P = 0.0001). All 
  subgroups experienced a PFS benefit with bevacizumab 
(sex, age, baseline VEGF level, lung metastases, number of 
metastatic sites, Memorial Sloan-Kettering Cancer Center 
[MSKCC] score). Overall, 70% of patients experienced any 
tumor shrinkage on bevacizumab/IFN compared with 39% 
in the control group. ORR by Response Evaluation Criteria 
In Solid Tumors was 31% vs 13%. Time to response was 
2.2 months with a median duration of 13.5 months in the 
bevacizumab-containing arm.
Time to treatment failure was also significantly improved 
over the control group: 7.7 months vs 4.4 months (HR = 0.73; 
95% CI, 0.62–0.87, P = 0.0003). The median duration of 
treatment was 9.7 months compared with 5.1 months in 
favor of the bevacizumab-containing arm. Median dose 
intensity of IFN was 91% in the bevacizumab arm and 96% 
in the control group. The most commonly reported adverse 
events in both arms were fatigue (13% vs 8%) and asthe-
nia (11% vs 7%). Both fatigue and asthenia were thought 
more likely IFN-related toxicities, but they did occur with 
a slightly higher frequency in the bevacizumab group. The 
most   common grade $3 adverse event associated with 
bevacizumab therapy were protei  nuria (8%) and hyperten-
sion (6%). Bevacizumab/  placebo was   discontinued due to 
toxicity in 23% of   bevacizumab patients compared with 5% 
of the control group; IFN was discontinued in 22% and 12%, 
respectively.
Given the significant nearly 5-month PFS benefit at the 
preplanned final analysis, the trial was unblinded early, and 
the Data Safety and Monitoring Board recommended that even 
patients who had not progressed on IFN   crossover to receive 
bevacizumab. Thirteen patients eventually   crossed-over to 
receive bevacizumab. Using   intent-  to-treat analysis, the 
final median OS was 23.3 months in the   investigational arm 
compared with 21.3 months in the control group (unstratified 
HR = 0.91; 95% CI, 0.76–1.10, P = 0.34). The advantage was 
more robust under analysis stratified for Motzer risk score and 
region with a 14% reduction in chance of death (HR = 0.86; 
95% CI, 0.72–1.04, P = 0.13) in patients who had received 
bevacizumab. The benefit of bevacizumab treatment persisted 
even with reduced doses of IFN to 3–6 MIU 3 times a week 
with a median OS of 26 months in those patients.
Although not statistically significant, there did appear 
to be a trend toward a survival benefit with the addition of 
  bevacizumab/IFN to IFN monotherapy.   Postprogression 
  therapy was a likely confounder as 55% of bevacizumab 
patients and 63% of control arm patients received a   second-line 
therapy. More than 35% of these patients received sunitinib 
or sorafenib, which became available in Europe in July 2006. 
Although unplanned, an exploratory analysis revealed a 
nonstatistically significant improvement in median OS in 
patients who received posttrial TKI therapy in favor of the 
bevacizumab arm (n = 113 vs 120, median OS 38.6 months vs 
33.5 months; HR = 0.8; 95% CI, 0.56–1.13, unstratified).
Delving into the question of the relative contribution 
of IFN to the combination’s efficacy, the AVOREN data 
were retrospectively interrogated to assess the impact of IFN OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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dose reductions on PFS.35 Of the 228 patients who received 
dose reductions of IFN, 64% were dose reduced to 6 MIU 
and 31% to 3 MIU. Approximately 60% of therapy was at the 
reduced dose. Upon comparing the full-dose IFN patients to 
reduced-dose IFN patients, the PFS benefit seen in the total 
study population persisted with HR = 0.63 (P = 0.0026) in the 
reduced-dose group compared with HR = 0.69 (P = 0.0007) 
in the full-dose group. There was a considerable reduction 
in grade 3/4 IFN-related adverse events from that reported 
within the 6 weeks before the reduction: 44% vs 18%. 
Because all patients received at least 1 full dose of IFN (9 
MIU), whether low-dose IFN is sufficient to achieve similar 
tumor responses or PFS as full dose could not be assessed. 
A prospective trial of bevacizumab plus low-dose IFN is 
ongoing.
On July 31, 2009, the FDA approved bevacizumab in com-
bination with IFN for the treatment of advanced RCC based 
on the results of the CALGB and AVOREN trials. The some-
what lower ORR and PFS in the CALGB trial was   postulated 
to be related to the higher percentage of   intermediate-risk 
and poor-risk patients, nonnephrectomized patients, the 
allowance of predominantly nonclear-cell   histologies, and the 
lack of independent review33 (Table 1). Given the increased 
toxicity of the combination and the impressive phase 2 PFS 
results with bevacizumab mono  therapy in a small randomized 
study evaluating the addition of erlotinib (median PFS = 8.5 
months), its use as a   monotherapy is again under investigation 
in an ongoing randomized phase 2 trial colloquially known as 
the BeST (Bevacizumab Sorafenib Tensirolimus) trial.27
These trials validated the use of antibody-mediated 
  inhibition of the VEGF ligand as a clinically relevant   strategy 
in RCC.33 Although a small survival benefit was seen in 
both studies, it was not statistically significant and likely 
  disadvantaged by the compounding effects of subsequent 
similar class therapies and improvements in supportive care 
since the pre-TKI era. The utility of bevacizumab/IFN likely 
lies in its ability to achieve response, to prolong PFS, and to 
offer a different side effect profile than the other currently 
available first-line agents for good-risk and   intermediate-risk 
patients, sunitinib and pazopanib (Table 2). Indirect 
Table 2 Comparative incidences of toxicities among bevacizumab and the multityrosine kinase inhibitors used to treat advanced renal 
cell carcinoma
Bevacizumab13,16,31–33 Sunitinib58,61–66 Sorafenib58,61,65,80–83 Pazopanib84–86
Fatigue ,10%–93% 54%–58% 29%–37% 19%–46%
Decline in cardiac 
ejection fraction
,1% 13%–21% ,1%–5%a ,1%
Hypertension 20%–28% 30% 17%–22% 40%–47%
Acute coronary 
syndrome, chest pain
1%–3% NR 2.9% 5%
Arteriothrombolic events 1%–4% 1.3% 1.7% 3%
venothrombolic events 3%–4% 2% ,1% NR
Hemorrhage/bleeding 5%–33% 18%–30% 15% 16%
Proteinuria 18%–71% Case reportsb Case reportsb 9%
Rash 0%–,5% 24%–27% 40%–41% 8%–16%
Hand–foot syndrome 0%–,5% 21%–29% 30%–60% 6%–11%
Diarrhea 20%–21% 58%–61% 43%–55% 52%–63%
Nausea ,10%–58% 49%–52% 19%–23% 26%–42%
vomiting ,10% 28%–32% 12%–16% 20%–21%
Mucositis/stomatitis 0%–,5% 30%–43% 5%–17% ,10%
Myelosuppression
Leukopenia NR 78% .10% 35%–37%
Neutropenia 7%–43% 72%–77% 18% 27%–34%
Anemia 16% 71%–79% 8%–44% ,10%–26%
Thrombocytopenia 6%–10% 65%–68% 12% 26%–32%
Transaminitis 8% 46%–56% 1%–10% 53%–54%
Hyperbilirubinemia 0%–5% 12%–20% ,1% 28%–36%
Hypothyroidism ,1% 14% ,1% 4%
infusion reaction ,3% n/a n/a n/a
Notes: aUnclear if the higher 5% incidence was associated with clinical heart failure in the Schmidinger study. bPostmarketing case reports.
Abbreviations: NA, not applicable; NR, not reported.OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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  comparison to the other available agents is inherently flawed 
but can be informative in lieu of direct head-to-head trials. 
In this case, it suggests that the efficacy of these 3 regimens is 
similar with PFS of 10–11 months and response rates between 
30%–40% (Table 3). Further study is needed to determine the 
best sequencing of the now 7 available regimens. Although 
everolimus is the only agent that has proven efficacy in a 
prospective randomized controlled trial after prior TKI fail-
ure,36 sunitinib and sorafenib do appear safe and active after 
patients have failed prior bevacizumab or the TKIs.37–42 For 
example, in a phase 2 multicenter study, 61 patients who had 
progressed on bevacizumab received sunitinib 50 mg orally 
daily on a 4-week on/2-week off schedule.39 The ORR was 
23% with a median duration of response of 44.1 weeks and 
median PFS of 30.4 weeks. Although direct investigation is 
needed to inform the most effective sequence, collectively 
these studies demonstrate that the VEGF inhibitors can have 
substantial activity sequentially.
In addition to its combination with IFN, several attempts 
at increasing bevacizumab’s efficacy have been evaluated 
by combining it with other multityrosine kinase and mTOR 
inhibitors effective in RCC. Multifaceted VEGF   blockade 
both at the level of the ligand with antibodies, such as 
  bevacizumab, and at the receptor with small molecule inhibi-
tors, like sunitinib or sorafenib, would seem to be the most 
rational and promising. In the small phase 1 studies that 
have been performed, enhanced antitumor activity has been 
observed but at the expense of concerning toxicities.43–45
Two phase 1 studies have evaluated the combination of 
sunitinib and bevacizumab. In the dedicated RCC trial, the 
maximally tolerated dose (MTD) was determined to be suni-
tinib 50 mg and bevacizumab 10 mg/kg with an ORR of 52% 
in the 25 patients treated.44 However, patients   experienced 
significant toxicity with 48%   discontinuing therapy. In the 
MTD group, grade $3 adverse events included hypertension 
in 83%, proteinuria in 50%, and thrombocytopenia in 50%. 
A notable pentad of symptoms including hemolytic anemia, 
thrombocytopenia, proteinuria,   hypertension, and renal insuf-
ficiency occurred in 8 patients. Two of the patients with severe 
  microangiopathic hemolytic anemia (MAHA) experienced 
severe   hypertension with subsequent development of reversible 
posterior   leukoencephalopathy syndrome (RPLS). Interestingly, 
with the exception of hypertension, these toxicities were not sig-
nificantly observed in the phase 1 trial of the same combination 
in advanced solid tumors.45 Of note, only 6 of those 48 patients 
were RCC patients. Only 1 dose-limiting toxicity of grade 4 
hypertension occurred in the dose below the MTD group, and no 
patient experienced MAHA in this trial. Grade 3 or greater toxic-
ity occurred in 87% of patients   including hypertension (47%), 
fatigue (24%),   thrombocytopenia (18%), proteinuria (13%), 
and hand-foot syndrome (13%). Although modestly active in 
this treatment-refractory group, the investigators admit dose 
modification and delays were frequently necessary for continued 
treatment particularly with the higher doses of each agent.
Combining bevacizumab with sorafenib, another multi-
TKI with activity against Raf kinase and VEGFR-2, appears to 
face similar tolerability challenges. In a phase 1 trial evaluat-
ing the combination of sorafenib 200 mg orally twice daily and 
bevacizumab 5–10 mg/kg every 2 weeks, toxicity would not 
permit either drug to be escalated to the standard single agent 
doses.43 By a median of 4 cycles, dose reduction of sorafenib 
was required in 74% of patients. Although clinical benefit 
was seen, greater intensity, rapidity, and frequency of toxicity 
were observed in the form of increased hypertension, massive 
proteinuria, thrombocytopenia, and hand-foot syndrome.
Bevacizumab’s use in combination with mTOR inhibition 
is also an area of considerable interest. There are at least 4 
ongoing trials evaluating the efficacy and safety of bevaci-
zumab and the IV mTOR inhibitor temsirolimus (www.clinical 
trials.gov, Accessed April 11, 2010). But perhaps the most 
Table 3 Efficacy results for the phase 3 VEGF inhibitor randomized controlled trials in treatment-naïve advanced RCC
Trial No PFS, mo OS, mo ORR,% Time to 
response, mo
Median duration 
response, mo
Bevacizumab + iFN-α vs 
placebo/iFN-α (AvOReN)30,31
649 10.2 vs 5.4  
(P = 0.0001)
23.3 vs 21.3 
(stratified, P = 0.1291)
31 vs 13 2.2 vs 3.7 13.5 vs 11.1
Bevacizumab + iFN-α vs  
iFN-α (CALGB 90206)32,33
732 8.5 vs 5.2  
(P , 0.0001)
18.3 vs17.4 
(stratified, P = 0.097)
25.5 vs 13.1 NR 11.9 vs 8.7
Sunitinib vs iFN-α62,63 750 11 vs 5 
P , 0.001
26.4 vs 21.8 
(P = 0.051, stratified, 
P = 0.049)
47 vs 12 NR NR
Pazopanib vs BSC/placebo86 233 11.1 vs 2.8 
P , 0.0001
NR 32 vs 4 3.0a 14.7a
Note: aAll treatment groups, not just treatment naïve.
Abbreviations: RCC, renal cell carcinoma; PFS, progression-free survival; OS, overall survival; iFN, interferon; NR, not reported; BSC, best supportive care.OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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advanced work has been done with the oral mTOR inhibitor, 
  everolimus.46 Two phase 1 trials initially demonstrated the safety 
and   tolerability of bevacizumab and everolimus in combination 
in advanced solid tumors. Zafar and colleagues47 investigated 
bevacizumab 10 mg/kg IV every 14 days and everolimus 5 
mg orally daily, escalating to 10 mg daily. No dose-limiting 
toxicities were observed in the 14 patients enrolled. From this 
study, the recommended phase 2 dosing of this combination was 
bevacizumab 10 mg/kg IV and everolimus 10 mg orally daily. 
The second phase 1 trial evaluated this combination with the 
addition of the EGFR-TKI erlotinib in a dose-escalation trial.48 
The initial dose of bevacizumab 10 mg/kg IV every 14 days 
and everolimus 5 mg orally daily was escalated to everolimus 
10 mg daily. If the escalated dose of everolimus was tolerable, 
then erlotinib was added at 75 mg orally daily. No grade 3 
toxicities were seen until erlotinib was added. With the addition 
of erlotinib, 2 of 6 patients experienced grade 3 mucositis and 
rash. The doses were de-escalated to bevacizumab 5 mg IV , 
everolimus 5 mg orally daily, and erlotinib 75 mg orally daily 
with no dose-limiting toxicities.
A phase 2 study of bevacizumab and everolimus has 
demonstrated efficacy in both treatment-naïve and treatment-
refractory (prior sunitinib and/or sorafenib) patients.46 Of 
the 50 treatment-naïve and 30 pretreated patients, median 
PFS were 9.1 months and 7.1 months with ORR of 30% and 
23%, respectively. Overall, the regimen was well tolerated 
with the most common grade 3 or greater toxicities being 
proteinuria (26%), mucositis/stomatitis (15%), fatigue (12%), 
and diarrhea (9%). The incidence of proteinuria was greater 
than expected, and 2 patients developed nephrotic syndrome. 
No symptomatic pneumonitis or MAHA was seen. The 
authors recognize the hazards of indirectly comparing phase 
2 results to phase 3 results of first-line sunitinib or second-line 
sorafenib, but admit the lack of increase in PFS or response 
rate compared with the available single agents may not sup-
port the combined use. Further study of these agents is needed 
before firmly drawing conclusions. Our center is accruing a 
single institution, phase 2 study evaluating this same com-
bination in RCC patients who are refractory to 1 or 2 prior 
VEGF TKIs. Additionally, a randomized phase 2 study is 
underway comparing the combination to bevacizumab/IFN 
in treatment-naïve patients.
In summary, bevacizumab has activity in advanced RCC 
and holds promise among investigators. As of February 2010, 
there were at least 50 trials (www.clinicaltrial.gov, Accessed 
February 10, 2010, “Bevacizumab + Renal Cell”) evaluating 
bevacizumab as monotherapy and in various combination 
therapies in RCC.
Bevacizumab-related toxicities
Many of the side effects related to bevacizumab have been 
discussed in the above sections. Bevacizumab is given 
rarely as a monotherapy in RCC or other solid tumors, so 
categorization of its individual side effects has been limited 
to results of small phase 1 and 2 series and assessment of 
toxicities deemed unexpected from the other investigational 
agent. In Yang’s small RCC series (n = 76/116) evaluating 
bevacizumab monotherapy, the most common toxicities at 
both the 3 mg/kg and 10 mg/kg dosages were hypertension 
and proteinuria, respectively.15,16 The proteinuria was not 
associated with decreased renal function. In the high-dose 
arm, epistaxis (8%), hypertension (14%; grade 3: 8%), 
hematuria (5%), and proteinuria (25%; grade 3: 3%) were 
all significantly increased from the placebo.
In the 2 large randomized phase 3 trials comparing its 
efficacy in combination with IFN, the primary toxicities 
attributed to bevacizumab included hypertension (26%; 
grade$3: 3%–10%), proteinuria (18%; grade $3: 7%–15%), 
and bleeding (33%; grade $3: 2%–3%).31,32 Well-established 
IFN-associated toxicities such as fatigue, asthenia, neutrope-
nia, fever, and depression were common in all patients in both 
trials but increased in the bevacizumab arm. In the AVOREN 
trial, the IFN-related toxicities occurred with a 10% higher 
incidence per patient year in the bevacizumab arm.
Cardiotoxicity with the VEGF inhibitors has warranted 
further study. Like the multi-TKIs that target VEGF sunitinib 
and sorafenib, bevacizumab has potential for   cardiac toxic-
ity most commonly in the form of hypertension (Table 2). 
Clinical sequelae of hypertension are rare but can progress 
to hypertensive crisis, hypertensive   encephalopathy, and 
RPLS.13,49,50 RPLS is an underappreciated but   recognizable 
clinicoradiographic syndrome characterized by a reversible 
cortical dysfunction with symptoms of headache, altered 
mental function, seizures, vomiting, and visual disturbances 
including cortical blindness. Characteristic imaging findings 
include white matter edema most commonly in the bilateral 
posterior cerebral hemispheres especially the parietal-
occipital lobes.51 If promptly recognized, it is reversible 
and controllable with treatment of hypertension, symptom 
management, and bevacizumab discontinuation.
More recently, the occurrence of bevacizumab-induced 
hypertension has been postulated to be predictive of response 
and outcome. This relationship between new or worsening 
hypertension and improved OS has been reported in solid 
tumor patients receiving bevacizumab-containing regimens 
and with other VEGF inhibitors.32,52–57 A retrospective 
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patients developed grade $2 hypertension compared with 
21% of the combination arm.32 With the exception of a 
slight increase in the number of patients who had had neph-
rectomy on the combination arm (92% vs 83%, P = 0.05), 
the authors report that the baseline prognostic factors were 
balanced between the 2 groups. There was a significant 
increase in both PFS and OS in patients who experienced 
grade $2   hypertension compared with those who did not at 
13.2 months vs 8 months (P , 0.001) and 41.6 months and 
16.2 months (P , 0.001), respectively.
A more concerning toxicity of left ventricular dysfunction 
has been observed with the multi-TKIs, especially   sunitinib. 
Rates of congestive heart failure and left ventricular 
  dysfunction have been cited as high as 28% with sunitinib 
in the RCC and gastrointestinal stromal tumors series.58–66 
Bevacizumab’s reported rate of congestive heart failure is 
significantly less at ,1% in the phase 3 RCC trials and 
1.2%–3.8% in the solid tumor trials.13,31–33 Previous exposure 
to anthracyclines, prior irradiation to the chest wall, and 
  baseline left ventricular systolic dysfunction may increase 
risk. Although many mechanistic theories   implicate   inhibition 
of PDGFR, ribosomal S6 kinase, and RAF1 kinase and their 
resultant downstream effects, the exact mechanisms behind 
this cardiotoxicity remain unclear.67 Other etiologies behind 
the treatment-induced hypertension include vascular rarefac-
tion, endothelial dysfunction, and/or altered nitrous oxide 
metabolism rather than a direct result of VEGF   inhibition or 
effects on the renovascular or adrenergic system.68 Bevaci-
zumab’s lower incidence of left ventricular systolic dysfunc-
tion, but similarly high rates of hypertension, lend support to 
the cardiotoxicity being a non-VEGF and nonhypertension-
mediated event.
The incidence of arterial thromboembolic events has 
been notable with bevacizumab. In a pooled analysis of the 
  randomized clinical trials of patients receiving   bevacizumab 
in combination with chemotherapy (n = 1745), 4.4% 
  compared with 1.9% being treated with chemotherapy 
alone experienced arterial thromboembolic events (cerebral 
  infarction, transient ischemic attacks, MI, angina, and a 
variety of other aterial thromboembolic events).13 In the 
advanced RCC trials, there was an increased incidence of 
cardiac ischemia/infarction (1% vs 0%) and thrombosis/
embolism (4% vs ,1%–2%) in the bevacizumab-treated 
patients.30,32
Proteinuria is a well-characterized complication of 
bevacizumab. In the RCC randomized controlled tri-
als, the   incidence of all grades was 18%–71% with 
bevacizumab therapy compared with 3%–10% in the IFN 
monotherapy group. VEGF is constitutively expressed by 
podocytes, and normal glomerular capillary endothelial cells 
have VEGF receptors.69 Using murine models, Sugimoto 
and colleagues70 demonstrated that anti-VEGF neutralizing 
antibodies and soluble VEGFR-1 protein (sFlt-1) induce 
proteinuria by rapid glomerular endothelial cell detachment 
and hypertrophy, which was associated with a concomitant 
downregulation of nephrin, a protein integral to the glomeru-
lar filtration process. Further investigating how bevacizumab 
might directly induce renal thrombotic microangiopathy, 
Eremina and colleagues69 developed a conditional gene 
murine model that targeted only podocytes, which are the 
major source of glomerular VEGF production. They con-
firmed that VEGF production by podocytes is necessary 
for glomerular endothelium integrity and that disruption 
by drug or genetic manipulation results in renal pathology 
consistent with the thrombotic microangiopathy induced by 
bevacizumab. It is unclear whether combinations of agents 
or sequential use of TKIs may exacerbate proteinuria and 
renal toxicity. There has been little reported proteinuria 
with everolimus monotherapy, but a higher than expected 
incidence of proteinuria was seen in the phase 2 combina-
tion trial with bevacizumab.46 Our anecdotal experience in an 
ongoing phase 2 trial evaluating bevacizumab and everolimus 
is consistent with the published phase 2 study as well. We 
recommend checking a urine protein before each dose of 
bevacizumab and following the hemoglobin, platelets, and 
creatinine for signs of MAHA and renal toxicity.
The risk of hemorrhage with bevacizumab is a black box 
warning and the FDA notes that severe or fatal   hemorrhage, 
including hemoptysis, gastrointestinal   bleeding,   central 
  nervous system hemorrhage, epistaxis, and vaginal   bleeding, 
has occurred up to 5-fold more in patients   receiving 
  bevacizumab.13 In the 2 RCC trials, the incidence of all 
grade hemorrhage/bleeding was 5%–33% with bevacizumab 
compared with ,1%–9% in the control group; 1%–3% of the 
bevacizumab-attributable bleeding was grade $3 in nature.
Wound-healing complications such as wound dehiscence 
and delayed healing have been reported in patients receiving 
bevacizumab. Animal models demonstrate that antibody 
neutralization of VEGF inhibits wound granulation tissue 
and that VEGF stimulates epithelialization and collagen 
deposition in wounds.71,72 The incidence of wound-healing 
complications in the phase 3 RCC trials was only 1% and not 
significantly increased compared with the control group.31 
This complication may be more germane to the growing use OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
187
Bevacizumab experience in advanced renal cell carcinoma
of these agents preoperatively to achieve downsizing of the 
tumor and safer surgeries.73–78 M.D. Anderson has reported the 
largest series of patients undergoing VEGF inhibitor therapy 
before cytoreductive open or laparoscopic nephrectomy.76 
They retrospectively analyzed 44 patients who received either 
bevacizumab, sorafenib, or sunitinib before nephrectomy and 
compared the complications to a matched cohort of 58 patients 
who received up-front surgery. Bevacizumab was held for at 
least 4 weeks before surgery. Their initial review reported no 
difference in operative time, estimated blood loss, amount 
of transfused blood products, or overall hospital stay, but 
an updated analysis 2 years later demonstrated significant 
  differences in superficial wound-healing complications (odds 
ratio = 19.7, P , 0.01) and delays in starting adjuvant therapy 
by about 17 days (48.8 days vs 31.7 days, P , 0.01).79
A prospective study evaluated the presurgical   feasibility 
and safety of bevacizumab (with or without erlotinib) in 
50 treatment-naïve metastatic RCC patients.75 After 2 cycles 
of presurgical bevacizumab, 52% experienced primary tumor 
reduction and the majority (84%) underwent nephrectomy. 
There was a notable incidence of wound dehiscence and 
delayed wound healing at 4 weeks postnephrectomy. Wound 
dehiscence complicated the postoperative course of 5 patients 
requiring either treatment discontinuation (n = 3) or delay 
(n = 2, median time delay: 20.5 days). The incidence of 
delayed superficial wound healing was significantly higher 
(21% vs 2%, P , 0.001) with presurgical bevacizumab 
than in a historic matched cohort of 101 patients who had 
undergone up-front surgery. Given the estimated half-life 
of approximately 20 days, bevacizumab should be held for 
at least 4–6 weeks before surgery when possible and should 
be discontinued in patients with severe wound-healing 
complications.13
In summary, bevacizumab commonly induces   hypertension 
and proteinuria and in combination with IFN, fatigue and 
asthenia. Concerning complications can include thromboem-
bolic events, hemorrhage,   gastrointestinal   perforation, and 
rare infusion-related reactions. Its use may offer advantages 
compared with its first-line tyrosine kinase competitors in 
terms of no or lower incidences of hand-foot syndrome, left 
ventricular systolic dysfunction, anemia, thrombocytopenia, 
thyroid dysfunction, and liver toxicity (Table 2).
Conclusions
Bevacizumab plus IFN is now an FDA-approved option for 
first-line therapy in metastatic RCC. Acknowledging the 
  limitations of indirect comparison, the regimen likely has 
equivalent efficacy to the other first-line, FDA-approved, 
VEGF-targeted agents, sunitinib and pazopanib. Enthusiasm 
for its use in combination with IFN is blunted by the increased 
costs and potential infusion-related reactions associated 
with its IV administration, the IFN-related toxicities, and 
the possible patient dissatisfaction with the inconvenience 
of its nonoral formulation. Advantages include a somewhat 
different toxi  city profile from the multi-TKIs and assurance 
of patient compliance with its IV administration. Ongoing 
studies are assessing its utility in combination with other 
targeted agents and immunotherapies and will revisit its use 
as a monotherapy. Identification of patient and tumor-specific 
biomarkers to inform our choice of first-line therapy as well 
as the sequential use of the available agents to treat RCC is 
imperative.
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